The latest price target for Serina Therapeutics (AMEX:SER) was reported by HC Wainwright & Co. on August 28, 2025. The analyst firm set a price target for $15.00 expecting SER to rise to within 12 months (a possible 406.76% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Serina Therapeutics (AMEX:SER) was provided by HC Wainwright & Co., and Serina Therapeutics reiterated their buy rating.

There is no last upgrade for Serina Therapeutics

There is no last downgrade for Serina Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Serina Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Serina Therapeutics was filed on August 28, 2025 so you should expect the next rating to be made available sometime around August 28, 2026.

While ratings are subjective and will change, the latest Serina Therapeutics (SER) rating was a reiterated with a price target of $15.00 to $15.00. The current price Serina Therapeutics (SER) is trading at is $2.96, which is out of the analyst’s predicted range.